PJWCreative, Author at HighField Bio

August 20, 2021 in Uncategorized

Experiences with UDesign

Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Phasellus hendrerit. Pellentesque aliquet nibh nec urna. In nisi neque, aliquet vel, dapibus id, mattis vel, nisi. Sed pretium, ligula sollici ...

September 30, 2020 in References

When liposomes met antibodies: Drug delivery and beyond

PJWCreative 0 Like Post Comments Off

September 9, 2020 in Publications

Advanced Drug Delivery Reviews: When Liposomes Met Antibodies: Drug Delivery and Beyond

PJWCreative 0 Like Post Comments Off

September 3, 2020 in Publications

When liposomes met antibodies: Drug delivery and beyond

PJWCreative 0 Like Post 0 Comment

June 24, 2020 in References

A single-valent long-acting human CD47 antagonist enhances antibody directed phagocytic activities

PJWCreative 0 Like Post 0 Comment

March 2, 2020 in Publications

Asian Journal of Pharmaceutical Sciences: Oral Uptake and Persistence of the FnAb-8 Protein Characterized by In Situ Radio-labeling and PET/CT Imaging

PJWCreative 0 Like Post Comments Off

September 28, 2019 in References

Formulation optimization of an ephrin A2 targeted immunoliposome encapsulating reversibly modified taxane prodrugs

PJWCreative 0 Like Post 0 Comment

November 30, 2018 in References

Global immune fingerprinting in glioblastoma patient peripheral blood reveals immune-suppression signatures associated with prognosis

PJWCreative 0 Like Post 0 Comment

November 2, 2018 in Publications

Global immune fingerprinting in glioblastoma patient peripheral blood reveals immune-suppression signatures associated with prognosis

PJWCreative 0 Like Post 0 Comment

October 26, 2018 in References

Safety and pharmacokinetics of MM-302, a HER2-targeted antibody–liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study

PJWCreative 0 Like Post 0 Comment

ASCO 2025 Abstract: First in human PK analysis of antibody conjugated liposome encapsulating doxorubicin (HF-K1) in advanced cancer patients: Comparison with ADCs.

AACR 2025 Poster: Myeloid cell targeted immune modulation in solid tumor and brain tumor patients: an analysis of NCTO5388487 phase 1 study data.

HighField Biopharmaceuticals Files INDs for Two ADCplex™ Immunoliposomes with Different Cancer Killing Payloads to Overcome Limitations of Current ADCs

HighField Biopharmaceuticals’ Clearance for Phase 2 Trial of HF1K16, a Unique Myeloid Cell Directed Immune Modulator, Follows Phase 1 Results to be Presented at AACR 2025 Meeting

Studies by HighField Biopharmaceuticals Show Advantages of Lipid Structure Design for Applying LNP Non-Viral Gene Therapies to Complex Diseases

HighField Biopharmaceuticals Granted Clearance of IND in China for Clinical Trial of its Unique TRAFsomeTM T Cell Engager (HF50) To Treat Solid Tumor Cancers

Experiences with UDesign

When liposomes met antibodies: Drug delivery and beyond

Advanced Drug Delivery Reviews: When Liposomes Met Antibodies: Drug Delivery and Beyond

When liposomes met antibodies: Drug delivery and beyond

A single-valent long-acting human CD47 antagonist enhances antibody directed phagocytic activities

Asian Journal of Pharmaceutical Sciences: Oral Uptake and Persistence of the FnAb-8 Protein Characterized by In Situ Radio-labeling and PET/CT Imaging

Formulation optimization of an ephrin A2 targeted immunoliposome encapsulating reversibly modified taxane prodrugs

Global immune fingerprinting in glioblastoma patient peripheral blood reveals immune-suppression signatures associated with prognosis

Global immune fingerprinting in glioblastoma patient peripheral blood reveals immune-suppression signatures associated with prognosis

Safety and pharmacokinetics of MM-302, a HER2-targeted antibody–liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study